Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients
A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
- Legemiddel: Placebo
- Legemiddel: BIIL 284 BS, low dose, pediatric patients
- Legemiddel: BIIL 284 BS, medium dose, pediatric patients
- Legemiddel: BIIL 284 BS, high dose, pediatric patients
- Legemiddel: BIIL 284 BS, low dose, adult patients
- Legemiddel: BIIL 284 BS, medium dose, adult patients
- Legemiddel: BIIL 284 BS, high dose, adult patients
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- All participants in the study were cystic fibrosis patients:
- Male or female ≥6 years (pediatrics 6 - 17 years; adult ≥18 years); minimum weight requirement of 20 kg
- Confirmed diagnosis of CF (positive sweat chloride ≥60 milliequivalents (mEq)/liter (by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF phenotype
- Forced expiratory volume in one second (FEV1) >25% predicted (using prediction equation's of Knudson)
- Clinically stable with no evidence of acute upper or lower respiratory tract infection or current pulmonary exacerbation within 2 weeks of screening
- Females of child bearing potential needed to have a negative pregnancy test at screening and, if sexually active, had to be willing to use a double-barrier form of contraception for the duration of the study
- The patient or the patient's legally acceptable representative had to be able to give informed consent in accordance with international conference of harmonization (ICH) good clinical practice (GCP) guidelines and local legislation
- The patient must be able to swallow the BIIL 284 BS tablet whole
- Patients taking a chronic medication must be willing to continue this therapy for the entire duration of the study
Exclusion Criteria:
- Patients with a history of allergy/hypersensitivity (including medication allergy) which is deemed relevant to the trial as judged by the Investigator
- Patients who had participated in another study with an investigational drug within one month or 6 half-lives (whichever is greater) preceding the screening visit
- Patients with known substance abuse, including alcohol or drug abuse, within 30 days prior to screening
- Patients who participated in excessive physical activities (e.g. strenuous sporting events) within 24 hours before the study
- Female patients who were pregnant or lactating
- Patients who were unable to comply with breakfast requirements prior to dosing
- Patients who had received IV, oral or inhaled antibiotics or corticosteroids for a pulmonary exacerbation within 2 weeks of screening
- Patients who had started a new chronic medication for CF within 2 weeks of screening
- Patients with documented persistent colonization with B. cepacia (defined as more than one positive culture within the past year)
- Patients with clinically significant findings on chest x-ray which in the opinion of the Investigator precludes the patient's participation in the trial
- Patients with oxyhemoglobin saturation in room air <90% by pulse oximetry
- Patients with hemoglobin <9.0 g/dL; platelets <100x109/L; serum glutamic-oxaloacetic transaminase (ALT) or serum glutamic-pyruvic transaminase (AST) >2 times the upper limit of normal; creatinine >1.8 mg/dL at screening
- Clinically significant disease or medical condition other than CF or CF-related conditions that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data. This includes significant hematological, hepatic, renal, cardiovascular, and neurologic disease. Patients with diabetes may participate if their disease is under good control prior to screening.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
|
|
Eksperimentell: BIIL 284 BS, lav dose hos pediatriske pasienter
|
|
|
Eksperimentell: BIIL 284 BS, medium dose in pediatric patients
|
|
|
Eksperimentell: BIIL 284 BS, high dose in pediatric patients
|
|
|
Eksperimentell: BIIL 284 BS, low dose in adult patients
|
|
|
Eksperimentell: BIIL 284 BS, medium dose in adult patients
|
|
|
Eksperimentell: BIIL 284 BS, høy dose hos voksne pasienter
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Changes from baseline in physical examination
Tidsramme: Pre-dose and up to 5 days after drug administration
|
Pre-dose and up to 5 days after drug administration
|
|
Number of patients with clinically relevant changes in vital signs (blood pressure, pulse rate, respiratory rate, body temperature)
Tidsramme: Pre-dose, up to 5 days after drug administration
|
Pre-dose, up to 5 days after drug administration
|
|
Changes from baseline in spirometry
Tidsramme: Pre-dose and up to 5 days after drug administration
|
Pre-dose and up to 5 days after drug administration
|
|
Changes from baseline in oximetry
Tidsramme: Pre-dose and up to 5 days after drug administration
|
Pre-dose and up to 5 days after drug administration
|
|
Number of patients with clinically relevant changes in 12-lead ECG
Tidsramme: Pre-dose, up to 5 days after drug administration
|
Pre-dose, up to 5 days after drug administration
|
|
Number of patients with clinically relevant changes in laboratory evaluation
Tidsramme: Pre-dose, up to 5 days after drug administration
|
Pre-dose, up to 5 days after drug administration
|
|
Number of patients with adverse events
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Plasma concentration-time profiles of BIIL 315 ZW in all dose groups
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Plasma concentration-time profiles of BIIL 284 BS, BIIL 260 BS and BIIL 304 ZW in medium dose adult and high dose pediatric group
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Area under the concentration-time curve of the analytes in plasma (AUC)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Maximum measured concentration of the analytes in plasma (Cmax)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Time from dosing to the maximum concentration of the analytes in plasma (tmax)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Terminal half-life of the analytes in plasma (t1/2)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Total mean residence time of the analytes in the body (MRTtot)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Terminal rate constant of the analytes in plasma (λz)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Apparent clearance of the analytes in plasma following extravascular administration (CL/F)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
|
Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)
Tidsramme: Up to 5 days after drug administration
|
Up to 5 days after drug administration
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 543.36
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .